公开(公告)号：KR101346132B1

公开(公告)日：2013-12-31

申请号：KR1020130016915

申请日：2013-02-18

Applicant: 강원대학교산학협력단

Inventor： 이한수 ,  진영준 ,  변희정 ,  이문성 ,  최종선

IPC: C07K16/24 ,  C12N15/13 ,  A61K39/395 ,  A61P35/00

Abstract: The present invention relates to an anti-MIC-1 monoclonal antibody, MBM-14 inhibiting angiogenesis of MIC-1, and more specifically, to an antibody which specifically combines to MIC-1 containing a light chain variable region with amino acid sequences 1,2 and 3 on complementarity determining regions which are CDR1, CDR2 and CDR3 and heavy chain variable region with amino acid sequences 4,5 and 6 on complementarity determining regions which are CDR1, CDR2 and CDR3. The antibody of the present invention is capable of effectively suppressing angiogenesis induced by MIC-1. Therefore, growth and metastasis of tumors can be stopped, and by using the present invention, treatments can be possible not only cancer, but also diseases related to angiogenesis such as arthritis, diabetes, retina disease, arteriosclerosis and psoriasis. Such treatments can be possible since the antibody of the present invention specifically combines to MIC-1 to disturb combination between MIC-1 and a receptor. In addition, antibodies with improved treatments effects can be invented based on the information of the antibody of the present invention.

Abstract translation: 本发明涉及抗MIC-1单克隆抗体，MBM-14抑制MIC-1的血管生成，更具体地说，涉及与含有轻链可变区的MIC-1与氨基酸序列1， 2和3对互补决定区是CDR1，CDR2和CDR3，重链可变区与氨基酸序列4,5和6互补决定区是CDR1，CDR2和CDR3。 本发明的抗体能够有效抑制由MIC-1引起的血管生成。 因此，可以停止肿瘤的生长和转移，并且通过使用本发明，不仅可以进行癌症治疗，还可以进行与血管生成相关的疾病如关节炎，糖尿病，视网膜疾病，动脉硬化和牛皮癣的治疗。 这样的处理是可能的，因为本发明的抗体与MIC-1特异性结合以干扰MIC-1和受体之间的组合。 此外，可以基于本发明的抗体的信息来发明具有改善的治疗效果的抗体。

公开(公告)号：KR101346181B1

公开(公告)日：2014-01-03

申请号：KR1020130016907

申请日：2013-02-18

Applicant: 강원대학교산학협력단

Inventor： 이한수 ,  진영준 ,  이재섭 ,  이문성 ,  김영명

IPC: C07K16/24 ,  C12N15/13 ,  C12N15/70

Abstract: The present invention relates to an anti-MIC-1 monoclonal antibody inhibiting the induction of angiogenesis by MIC-1 and, more particularly, to an antibody specifically binding to MIC-1 comprising: light chain variable regions in which complementarity determining regions, CDR1, CDR2, and CDR3 have amino acid sequences for sequence number 1, 2, and 3 respectively; and heavy chain variable regions in which complementarity determining regions, CDR1, CDR2, and CDR3 have amino acid sequences for sequence number 4, 5, and 6 respectively. The antibody in the present invention effectively inhibits angiogenesis induced by MIC-1, thereby blocking tumor growth and metastasis. And the treatment for disorders related to hyper angiogenesis, which have been increasing in number recently, such as arthritis, diabetes, retina diseases, atherosclerosis, and psoriasis, etc. as well as cancers can be expected. The effectiveness is considered because the antibody in the present invention specifically binds to MIC-1 and interrupts the binding between MIC-1 and receptor thereof. Also, the development of more effective antibody can be expected by modifying the information about the antibody in the present invention.

Abstract translation: 本发明涉及通过MIC-1抑制血管生成诱导的抗MIC-1单克隆抗体，更具体地，涉及与MIC-1特异性结合的抗体，所述抗体包含：轻链可变区，其中互补决定区CDR1， CDR2和CDR3分别具有序列号1,2和3的氨基酸序列; 和重链可变区，其中互补决定区CDR1，CDR2和CDR3分别具有序列号4,5和6的氨基酸序列。 本发明中的抗体有效抑制由MIC-1诱导的血管发生，从而阻断肿瘤的生长和转移。 并且预期近年来一直在增加的关于高血管发生的疾病如关节炎，糖尿病，视网膜疾病，动脉粥样硬化和牛皮癣等以及癌症的治疗。 考虑到本发明的抗体与MIC-1特异性结合并中断MIC-1与其受体之间的结合，因此考虑到有效性。 此外，通过修改本发明中关于抗体的信息，可以预期开发更有效的抗体。